Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001360891 | SCV001556847 | uncertain significance | Glutaric aciduria, type 1 | 2022-07-12 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GCDH protein function. ClinVar contains an entry for this variant (Variation ID: 1052666). This variant has not been reported in the literature in individuals affected with GCDH-related conditions. This variant is present in population databases (rs759415410, gnomAD 0.01%). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 154 of the GCDH protein (p.Ala154Thr). |
Gene |
RCV002293531 | SCV002586756 | uncertain significance | not provided | 2022-04-22 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002341759 | SCV002637755 | uncertain significance | Inborn genetic diseases | 2024-02-26 | criteria provided, single submitter | clinical testing | The c.460G>A (p.A154T) alteration is located in exon 6 (coding exon 5) of the GCDH gene. This alteration results from a G to A substitution at nucleotide position 460, causing the alanine (A) at amino acid position 154 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003416261 | SCV004117635 | uncertain significance | GCDH-related disorder | 2023-01-30 | criteria provided, single submitter | clinical testing | The GCDH c.460G>A variant is predicted to result in the amino acid substitution p.Ala154Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.012% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-13004422-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Natera, |
RCV001360891 | SCV002086965 | uncertain significance | Glutaric aciduria, type 1 | 2019-12-10 | no assertion criteria provided | clinical testing |